Skip to main content

Table 2 CGM parameters and urinary glucose level of 24 participants treated with SGLT2-I

From: Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

CGM parameters

Before

Day 0

Day 3

Day 7

p value

MBG, mg/dL

201.4 ± 55.6

180.8 ± 43.2*

154.0 ± 29.1*

142.3 ± 20.2*

<0.001

SD, mg/dL

39.6 ± 13.5

34.7 ± 12.8

34.4 ± 12.8

31.7 ± 9.2*

0.006

CV, %

20.0 ± 5.5

19.1 ± 4.7

22.3 ± 6.7

22.6 ± 6.5

0.015

Time at >140 mg/dL, %

79.4 ± 24.7

74.7 ± 25.7

52.9 ± 25.6*

47.0 ± 23.7*

<0.001

Time at <70 mg/dL, %

0

0

0.2 ± 1.1

0.9 ± 3.6

0.355

Time at 70–140 mg/dL, %

20.6 ± 24.7

25.3 ± 25.7

46.8 ± 25.5*

52.1 ± 22.8*

<0.001

MAGE, mg/dL

106.9 ± 42.0

99.1 ± 38.8

96.3 ± 32.6

87.4 ± 25.2*

0.049

LAGE, mg/dL

147.5 ± 46.2

148.1 ± 51.0

132.9 ± 51.2

121.2 ± 38.3*

0.009

M value, mg/dL

47.7 ± 39.8

32.6 ± 27.1*

19.9 ± 15.2*

14.5 ± 6.7*

<0.001

MPPGE, mg/dL

80.8 ± 30.6

76.8 ± 34.9

85.5 ± 35.2

79.3 ± 23.4

0.472

Max, mg/dL

282.4 ± 64.8

271.4 ± 66.1

237.3 ± 53.0*

217.3 ± 31.4*

<0.001

Min, mg/dL

135.0 ± 43.9

123.3 ± 29.3

104.4 ± 19.4*

96.2 ± 22.1*

<0.001

BGBB, mg/dL

176.5 ± 51.0

170.5 ± 37.5

135.2 ± 30.5*

121.9 ± 18.9*

<0.001

BG1hAB, mg/dL

226.7 ± 56.7

207.4 ± 59.7

195.1 ± 38.9*

170.6 ± 28.6*

<0.001

BG2hAB, mg/dL

249.8 ± 60.0

218.9 ± 67.5*

204.5 ± 48.6*

183.1 ± 36.9*

<0.001

BGBL, mg/dL

206.5 ± 65.0

174.2 ± 60.6*

131.8 ± 39.8*

120.1 ± 25.6*

<0.001

BG1hAL, mg/dL

241.1 ± 78.1

202.9 ± 65.9*

179.3 ± 41.5*

169.1 ± 33.8*

<0.001

BG2hAL, mg/dL

229.8 ± 69.4

205.7 ± 67.6

182.5 ± 45.1*

171.4 ± 31.0*

<0.001

BGBD, mg/dL

169.2 ± 59.4

142.3 ± 36.7*

125.5 ± 28.8*

121.1 ± 28.0*

<0.001

BG1hAD, mg/dL

238.0 ± 68.0

204.6 ± 41.1*

192.7 ± 40.0*

183.1 ± 21.5*

<0.001

BG2hAD, mg/dL

248.4 ± 72.8

217.8 ± 58.0*

205.7 ± 45.4*

187.7 ± 33.3*

<0.001

Urinary glucose, g/day

18.8 ± 26.6

 

84.3 ± 31.9*

71.3 ± 31.7*

<0.001

  1. Data are mean ± SD or n (%)
  2. Repeated measures ANOVA was used to determine the association-treatment difference
  3. CGM continuous glucose monitoring, SGLT2-I sodium glucose cotransporter 2 inhibitor, MBG mean blood glucose, SD standard deviation, CV coefficient of variation, MAGE mean amplitude of glycemic excursions, LAGE largest amplitude of glycemic excursions, MPPGE mean postprandial glucose excursions, BG blood glucose, BB before breakfast, AB after breakfast, BL before lunch, AL after lunch, BD before dinner, AD after dinner
  4. * p < 0.05 for differences with the value at before treatment